Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Gyre Therapeutics (GYRE) Non Operating Income: 2009-2025

Historic Non Operating Income for Gyre Therapeutics (GYRE) over the last 16 years, with Sep 2025 value amounting to $727,000.

  • Gyre Therapeutics' Non Operating Income rose 1069.33% to $727,000 in Q3 2025 from the same period last year, while for Sep 2025 it was -$945,000, marking a year-over-year decrease of 260.69%. This contributed to the annual value of -$1.7 million for FY2024, which is 9.29% down from last year.
  • Gyre Therapeutics' Non Operating Income amounted to $727,000 in Q3 2025, which was up 601.38% from -$145,000 recorded in Q2 2025.
  • Gyre Therapeutics' 5-year Non Operating Income high stood at $727,000 for Q3 2025, and its period low was -$1.6 million during Q4 2024.
  • Its 3-year average for Non Operating Income is -$311,700, with a median of -$110,000 in 2024.
  • As far as peak fluctuations go, Gyre Therapeutics' Non Operating Income tumbled by 133,200.00% in 2023, and later soared by 1,069.33% in 2025.
  • Over the past 5 years, Gyre Therapeutics' Non Operating Income (Quarterly) stood at -$20,000 in 2021, then surged by 93.75% to -$1,000 in 2022, then crashed by 133,200.00% to -$237,000 in 2023, then crashed by 589.45% to -$1.6 million in 2024, then soared by 1,069.33% to $727,000 in 2025.
  • Its Non Operating Income was $727,000 in Q3 2025, compared to -$145,000 in Q2 2025 and $107,000 in Q1 2025.